

MEDIA RELEASE • MEDIENMITTEILUNG • COMMUNIQUE AUX MEDIAS

Cytos Biotechnology obtains additional votes to validly pass the convertible bond restructuring proposal. Going concern of Cytos thereby ensured subject to final approval of the bond restructuring proposal by the relevant courts.

Schlieren (Zurich), Switzerland, December 12, 2011 – Cytos Biotechnology Ltd. (“Cytos”) today announced that it has been successful in obtaining additional votes from bondholders to validly pass the convertible bond restructuring proposal as announced on October 20, 2011 and that all five resolutions have now been passed with the required quorum of two thirds of the outstanding nominal value of the outstanding 2.875% convertible bonds due in February 2012. The resolutions approved by the Bondholders' Meeting held on November 10, 2011 will now be submitted to, and will only become valid and binding upon final approval by, the superior composition authority of creditors of the canton of Zurich (“*Obere Kantonale Nachlassbehörde*”).

Cytos furthermore announced that it was able to refinance convertible bonds in the total nominal amount of CHF 1.225 million by entering into a mandatory convertible loan agreement in the same amount. Due to the mandatory conversion of this new loan into shares of the Company the overall financial indebtedness of the Company could be further reduced. The applicable conversion price of the mandatory convertible loan is CHF 2.50 per share which represents a premium of 29% to the volume weighted average share price of the last sixty trading days prior to the date of this press release. The agreement is conditional upon the final approval of the bond restructuring as specified above.

For further information please contact:

Cytos Biotechnology Ltd

Harry Welten

Chief Financial Officer

Tel.: +41 44 733 46 46

e-Mail: harry.welten@cytos.com

Website: www.cytos.com

About Cytos Biotechnology Ltd

Cytos Biotechnology Ltd is a Swiss public biotechnology company that specializes in the discovery, development and commercialization of a new class of biopharmaceutical products – the Immunodrugs™. Immunodrugs™ are intended for use in the treatment and prevention of common chronic diseases, which afflict millions of people worldwide. Immunodrugs™ are designed to instruct the patient's immune system to produce desired therapeutic antibody or T cell responses that modulate chronic disease processes. The Immunodrug™ candidates are developed both in-house and together with Novartis, Pfizer and Pfizer Animal Health. Founded in 1995 as a spinoff from the Swiss Federal Institute of Technology (ETH) in Zurich, the Company is located in Schlieren (Zurich). Cytos Biotechnology Ltd is listed on the main segment at the SIX Swiss Exchange (SIX:“CYTN”).

This foregoing press release may contain forward-looking statements that include words or phrases such as “are intended for”, “are designed to”, “will”, or other similar expressions. These forward-looking statements are subject to a variety of significant uncertainties, including scientific, business, economic and financial factors, and therefore actual results may differ significantly from those presented. There can be no assurance that any further therapeutic entities will enter clinical trials, that clinical trial results will be predictive for future results, that therapeutic entities will be the subject of filings for regulatory approval, that any drug candidates will receive marketing approval from the U.S. Food and Drug Administration or equivalent regulatory authorities, or that drugs will be marketed successfully. Against the background of these uncertainties readers should not rely on forward-looking statements. The company assumes no responsibility to update forward-looking statements or adapt them to future events or developments. This document does not constitute an offer or invitation to subscribe or purchase any securities of Cytos Biotechnology Ltd.